[go: up one dir, main page]

NO20083358L - Piperasinyl derivater som modulatorer for kjemokine reseptor aktivitet - Google Patents

Piperasinyl derivater som modulatorer for kjemokine reseptor aktivitet

Info

Publication number
NO20083358L
NO20083358L NO20083358A NO20083358A NO20083358L NO 20083358 L NO20083358 L NO 20083358L NO 20083358 A NO20083358 A NO 20083358A NO 20083358 A NO20083358 A NO 20083358A NO 20083358 L NO20083358 L NO 20083358L
Authority
NO
Norway
Prior art keywords
modulators
piperasinyl
derivatives
chemokine receptor
receptor activity
Prior art date
Application number
NO20083358A
Other languages
English (en)
Inventor
Percy H Carter
Cullen L Cavallaro
George V De Lucca
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of NO20083358L publication Critical patent/NO20083358L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
    • C07D295/182—Radicals derived from carboxylic acids
    • C07D295/185—Radicals derived from carboxylic acids from aliphatic carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/56—Amides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Vascular Medicine (AREA)
  • Neurosurgery (AREA)
  • Transplantation (AREA)
  • Hospice & Palliative Care (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Foreliggende søknad beskriver modulatorer av MIP-1a med formel (I): (I) eller stereoisomerer eller farmasøytisk akseptable salter derav, hvor m, T, W, R1, R4, R5, R5a og R5b er som definert her. I tillegg er det beskrevet metoder for behandling og forhindring av inflammatoriske sykdommer så som astma og allergiske sykdommer, så vel som autoimmune patologier så som revmatoid artritt og aterosklerose ved anvendelse av nevnte modulatorer.
NO20083358A 2006-01-27 2008-07-31 Piperasinyl derivater som modulatorer for kjemokine reseptor aktivitet NO20083358L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US76305106P 2006-01-27 2006-01-27
US11/625,889 US7615556B2 (en) 2006-01-27 2007-01-23 Piperazinyl derivatives as modulators of chemokine receptor activity
PCT/US2007/061014 WO2007087585A1 (en) 2006-01-27 2007-01-25 Piperazinyl derivatives as modulators of chemokine receptor activity

Publications (1)

Publication Number Publication Date
NO20083358L true NO20083358L (no) 2008-09-30

Family

ID=37969746

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20083358A NO20083358L (no) 2006-01-27 2008-07-31 Piperasinyl derivater som modulatorer for kjemokine reseptor aktivitet

Country Status (7)

Country Link
US (2) US7615556B2 (no)
EP (1) EP1973880B1 (no)
JP (1) JP2009524691A (no)
KR (1) KR20080090538A (no)
AU (1) AU2007208031A1 (no)
NO (1) NO20083358L (no)
WO (1) WO2007087585A1 (no)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2347775T3 (da) 2005-12-13 2020-07-13 Harvard College Skabeloner til celletransplantation
US7601844B2 (en) * 2006-01-27 2009-10-13 Bristol-Myers Squibb Company Piperidinyl derivatives as modulators of chemokine receptor activity
EP2173713B1 (en) * 2007-07-24 2016-02-17 Bristol-Myers Squibb Company Piperidinyl derivatives as modulators of chemokine receptor activity
CN101808990B (zh) * 2007-07-24 2012-09-05 百时美施贵宝公司 作为趋化因子受体活性调节剂的哌啶衍生物
US10328133B2 (en) 2008-02-13 2019-06-25 President And Fellows Of Harvard College Continuous cell programming devices
ES2424661T3 (es) 2008-03-07 2013-10-07 Bristol-Myers Squibb Company Hidroxialcanil amidas como moduladores de la actividad del receptor de quimioquina
US10793515B2 (en) 2008-03-19 2020-10-06 Aurimmed Pharma, Inc. Compounds advantageous in the treatment of central nervous system diseases and disorders
WO2009117515A2 (en) 2008-03-19 2009-09-24 Aurimmed Pharma, Inc. Novel compounds advantageous in the treatment of central nervous system diseases and disorders
US20210130285A1 (en) 2008-03-19 2021-05-06 Aurimmed Pharma, Inc. Novel compounds advantageous in the treatment of central nervous system diseases and disorders
TWI433838B (zh) * 2008-06-25 2014-04-11 必治妥美雅史谷比公司 作為趨化因子受體活性調節劑之六氫吡啶衍生物
WO2011014871A1 (en) * 2009-07-31 2011-02-03 President And Fellows Of Harvard College Programming of cells for tolerogenic therapies
US8642622B2 (en) 2010-06-16 2014-02-04 Bristol-Myers Squibb Company Piperidinyl compound as a modulator of chemokine receptor activity
CN107648668B (zh) 2010-10-06 2021-06-18 哈佛学院董事会 用于基于材料的细胞疗法的可注射的成孔水凝胶
US9675561B2 (en) 2011-04-28 2017-06-13 President And Fellows Of Harvard College Injectable cryogel vaccine devices and methods of use thereof
KR20130064689A (ko) * 2011-12-08 2013-06-18 삼성전자주식회사 광굴절 복합체, 상기 광굴절 복합체를 포함하는 공간광 변조기 및 홀로그램 디스플레이 장치
FR2985256B1 (fr) * 2011-12-30 2016-03-04 Pitty Marc Henry Derives piperazinyles pour le traitement de cancers
CN104244929B (zh) 2012-04-16 2017-04-05 哈佛学院董事会 用于调节免疫反应的介孔二氧化硅组合物
US8716235B2 (en) 2012-04-18 2014-05-06 Albert Einstein College Of Medicine Of Yeshiva University Method for inhibiting metastasis by using anti-CCL3 antibodies
JP6664632B2 (ja) * 2013-09-30 2020-03-13 国立大学法人 東京大学 アディポネクチン受容体活性化化合物
US10682400B2 (en) 2014-04-30 2020-06-16 President And Fellows Of Harvard College Combination vaccine devices and methods of killing cancer cells
EP3250250A4 (en) 2015-01-30 2019-05-22 President and Fellows of Harvard College PERITUMORAL AND INTRATUMORAL MATERIALS FOR CANCER THERAPY
JP7094533B2 (ja) 2015-04-10 2022-07-04 プレジデント アンド フェローズ オブ ハーバード カレッジ 免疫細胞捕捉デバイスおよびその製造および使用方法
EP3411475B1 (en) 2016-02-06 2025-08-27 President and Fellows of Harvard College Recapitulating the hematopoietic niche to reconstitute immunity
CN115537372A (zh) 2016-07-13 2022-12-30 哈佛学院院长等 抗原呈递细胞模拟支架及其制备和使用方法
EP3493842A4 (en) 2016-08-02 2020-07-29 President and Fellows of Harvard College BIOMATERIALS TO MODULATE IMMUNE RESPONSES
WO2020061129A1 (en) 2018-09-19 2020-03-26 President And Fellows Of Harvard College Compositions and methods for labeling and modulation of cells in vitro and in vivo

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9104656D0 (en) 1991-03-05 1991-04-17 Zambeletti Spa L Pharmaceuticals
DE4243858A1 (de) 1992-12-23 1994-06-30 Thomae Gmbh Dr K Aminosäurederivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
US5459151A (en) 1993-04-30 1995-10-17 American Home Products Corporation N-acyl substituted phenyl piperidines as bronchodilators and antiinflammatory agents
US5777112A (en) 1994-06-13 1998-07-07 Merck & Co., Inc Piperazine compounds promote release of growth hormone
CA2226740A1 (en) * 1995-07-13 1997-01-30 Mitsuyoshi Azuma Piperazine derivative and its uses
FR2740134B1 (fr) * 1995-10-18 1998-01-09 Pf Medicament Derives d'amines cycliques d'aryl-piperazines, leur preparation et les compositions pharmaceutiques les contenant
DE69625575T2 (de) * 1995-10-25 2003-09-25 Senju Pharmaceutical Co., Ltd. Angiogense-Inhibitor
CA2249601A1 (en) 1996-04-03 1997-10-23 Thorsten E. Fisher Inhibitors of farnesyl-protein transferase
WO1998017625A1 (en) 1996-10-22 1998-04-30 Daiichi Pharmaceutical Co., Ltd. Novel remedies for infectious diseases
US5847148A (en) * 1997-04-10 1998-12-08 Pharmacia & Upjohn Company Thiadiazole derivatives useful for the treatment of diseases related to connective tissue degradation
ZA987383B (en) 1997-08-19 2000-02-17 Lilly Co Eli Treatment of congestive heart failure with growth hormone secretagogues.
ZA987385B (en) 1997-08-19 2000-04-18 Lilly Co Eli Growth hormone secretagogues.
EP1009758B1 (en) * 1997-08-29 2005-06-01 Tularik Limited Meta-benzamidine derivatives as serine protease inhibitors
JP4949552B2 (ja) * 1998-04-16 2012-06-13 エンサイシブ・フアーマシユーテイカルズ，インコーポレイテツド インテグリンのそれの受容体への結合を阻害するｎ，ｎ−ジ置換アミド
US6391865B1 (en) * 1999-05-04 2002-05-21 Schering Corporation Piperazine derivatives useful as CCR5 antagonists
EP1187614A4 (en) 1999-06-04 2005-06-22 Merck & Co Inc SUBSTITUTED PIPERIDINES THAN MELANOCORTIN-4 RECEPTOR AGONISTS
DE19939910A1 (de) 1999-08-23 2001-03-01 Morphochem Ag Neue Verbindungen, die Tryptase-Aktivität hemmen
DE10041402A1 (de) * 2000-08-23 2002-03-14 Morphochem Ag Neue Verbindungen, die Faktor Xa-Aktivität inhibieren
AUPQ386899A0 (en) * 1999-11-04 1999-11-25 Fujisawa Pharmaceutical Co., Ltd. Peptide compounds
JP2001354657A (ja) 2000-06-09 2001-12-25 Sds Biotech:Kk 置換ピペラジン誘導体及び農園芸用殺菌剤
DE10056312A1 (de) * 2000-11-14 2002-05-16 Bayer Ag Substituierte Amidoalkyluracile und ihre Verwendung
US6861424B2 (en) * 2001-06-06 2005-03-01 Schering Aktiengesellschaft Platelet adenosine diphosphate receptor antagonists
US7115628B2 (en) 2001-07-18 2006-10-03 Merck & Co., Inc. Bridged piperidine derivatives as melanocortin receptor agonists
US6977264B2 (en) 2001-07-25 2005-12-20 Amgen Inc. Substituted piperidines and methods of use
AU2002326823B2 (en) 2001-09-06 2005-12-15 Merck Sharp & Dohme Corp. 17beta-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases
US6875772B2 (en) * 2001-11-30 2005-04-05 Schering Corporation [1,2,4]-Triazole bicyclic adeonsine A2a receptor antagonists
CN1816551A (zh) * 2001-12-20 2006-08-09 Osi药物公司 吡咯并嘧啶A2b选择性拮抗剂化合物,它们的合成及用途
AU2002366811B2 (en) * 2001-12-20 2009-01-15 Osi Pharmaceuticals, Inc. Pyrimidine A2B selective antagonist compounds, their synthesis and use
US7041681B2 (en) 2002-04-29 2006-05-09 Janssen Pharmaceutica N.V. Compounds as opioid receptor modulators
US20050256130A1 (en) 2002-06-12 2005-11-17 Chemocentryx, Inc. Substituted piperazines
GB0224917D0 (en) 2002-10-25 2002-12-04 Novartis Ag Organic compounds
CA2512886A1 (en) 2003-02-28 2004-09-10 Galderma Research & Development, S.N.C. Ligands that modulate lxr-type receptors
MXPA05013474A (es) 2003-06-13 2006-03-09 Schering Ag Derivados de quinolilamida como antagonistas de ccr-5.
GB0315203D0 (en) 2003-06-28 2003-08-06 Celltech R&D Ltd Chemical compounds
CN1942186B (zh) * 2004-03-09 2010-10-06 国家卫生研究院 吡咯烷化合物
GB0412468D0 (en) 2004-06-04 2004-07-07 Astrazeneca Ab Chemical compounds
US7723360B2 (en) 2004-08-06 2010-05-25 Boehringer Ingelheim International Gmbh Alkyl-and piperidine-substituted benzimidazole derivatives

Also Published As

Publication number Publication date
US20070179148A1 (en) 2007-08-02
EP1973880A1 (en) 2008-10-01
AU2007208031A1 (en) 2007-08-02
US7615556B2 (en) 2009-11-10
EP1973880B1 (en) 2013-08-07
JP2009524691A (ja) 2009-07-02
US20090298845A1 (en) 2009-12-03
US8609664B2 (en) 2013-12-17
WO2007087585A1 (en) 2007-08-02
KR20080090538A (ko) 2008-10-08

Similar Documents

Publication Publication Date Title
NO20083358L (no) Piperasinyl derivater som modulatorer for kjemokine reseptor aktivitet
NO20083359L (no) Piperidinyl derivater som modulatorer for kjemokine reseptor aktivitet
NO20060717L (no) Sykliske derivater som modulatorer av kjemokin reseptoractivitet
NO20060719L (no) Substituerte cykloalkylaminderivater som modulatorer av kemokin reseptor aktivitet
NO20092286L (no) Nitrogenhaldige heterosykliske forbindelser og anvendelse derav
NO20084418L (no) Azolopyridin-3-on derivater som inhibitorer av endoteliallipase
NO20071246L (no) Kinazolinonderivater og deres anvendelse som B-RAF-inhibitorer.
TW200716648A (en) Heterocycles as nicotinic acid receptor agonists for the treatment of dyslipidemia
NO20074207L (no) Substituted pyrido(2,3-d) pyrimidine derivatives and pharmaceutical compositions useful as medicines for the treatment of autoimmune disorders
NO20083427L (no) Cystoksiske midler omfattende nye tomaymycinderivater og deres terapeutiske anvendelse
MX2009010503A (es) Compuestos heterociclicos antiviricos.
NO20051100L (no) Pyrazolsammensetninger anvendelige som GSK-3-inhibitorer
NO20082090L (no) Pyridopyrimidinoninhibitorer av P13K alfa
NO20082159L (no) Triazolopyridinderivater som inhibitorer av lipaser og fosfolipaser
NO20071776L (no) Kinoksaliner som B RAF inhibitorer.
WO2008094992A3 (en) 2-aminopyridine derivatives useful as kinase inhibitors
NO20066055L (no) Pyridinderivater
TW200738729A (en) Heterocycles as nicotinic acid receptor agonists for the treatment of dyslipidemia
NO20061454L (no) Compounds having CRTH2 antagonist activity
NO20091590L (no) Heterocykliske amidforbindelser anvendbare som kinaseinhibitorer
NO20085099L (no) Puritonderivativer som HM74A agonister
NO20070588L (no) Piperidinderivater som NK1-antagonister.
NO20082496L (no) Pyrazinderivater
NO20090664L (no) Purinderivater som A2A-agonister
NO20071574L (no) Arylsulfonylstilbenderivater for behandling av insomni og beslektede tilstander.

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application